Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: December 24, 2011
Last updated: January 1, 2012
Last verified: December 2011

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.

Condition Intervention
Genetic: gene expression analysis
Genetic: gene rearrangement analysis
Genetic: polymerase chain reaction
Genetic: protein analysis
Genetic: western blotting
Other: laboratory biomarker analysis
Other: mass spectrometry

Study Type: Observational
Official Title: The Role of AF1q in Progression of Leukemia

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Subcellular localization of the MLL-AF1q fusion protein in leukemia cells [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: December 2011
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:


  • To determine the subcellular localization of the MLL-AF1q fusion protein in leukemia cells.

OUTLINE: Cryopreserved specimens are analyzed for MLL-AF1q fusion protein and AF1 gene expression by mass spectrometry, western blot analysis, semi-quantitative PCR, and qPCR.


Ages Eligible for Study:   up to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Cryopreserved acute myeloid leukemia specimens


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01500499

Sponsors and Collaborators
Children's Oncology Group
Principal Investigator: Julie D. Saba, MD, PhD Children's Hospital & Research Center Oakland
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office Identifier: NCT01500499     History of Changes
Other Study ID Numbers: CDR0000721339, COG-AAML12B2
Study First Received: December 24, 2011
Last Updated: January 1, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult acute myeloid leukemia
childhood acute myeloid leukemia/other myeloid malignancies processed this record on March 03, 2015